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Abstract
To date, information on COVID-19 long-term post-recovery sequelae in children and adolescents remains scarce. A
retrospective descriptive cohort study was performed by collecting data on 92 patients (age ≤ 18 years). All were
evaluated during a face-to-face visit following a specially designed post-COVID-19 symptom assessment protocol at
the following stage: 1–3 months after COVID-19 onset. Among the 92 children, 45 (49%) were completely free of
any COVID-19-related symptoms, while 47 (51%) reported persistence of at least one symptom, in particular
tiredness, loss of taste and/or smell and headaches. The most common post-acute COVID-19 clinical features were
noted in children aged between 10 and 18 years. A detailed multidisciplinary follow-up of patients with COVID-19
seems relevant, whatever the severity of the symptoms.
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To the Editor,
Severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) infection causes a spectrum of character-
istics ranging from asymptomatic seroconversion to
severe coronavirus cases, sometimes with prolonged
symptoms [1]. Current data shows that prolonged symp-
tom duration is common not only in adults with severe
and non-severe coronavirus disease 2019 (COVID-19),
but also among children with COVID-19 [2–7]. Post-
acute COVID-19 clinical features vary widely. The most
commonly reported persistent symptoms after recovery
from COVID-19 among the symptomatic outpatients
were insomnia, fatigue, coughing, dyspnea, loss of taste
and/or smell and headaches [3, 5–7]. As noted by Hoang
et al., SARS-CoV-2 infection in children has a milder
clinical course commonly characterised by fever, cough,
rhinorrhea and myalgia/fatigue [8]. This contrasts with
adults, characterising a return to baseline health among
children with milder COVID-19, although the clinical
course is not sufficiently described.
Children’s Clinical University Hospital in Riga estab-
lished a post-acute outpatient follow-up service for
individuals who had recovered from COVID-19. Before
the start of December 2020, 3509 children were diag-
nosed with SARS-CoV-2 infection, representing approxi-
mately 8.6% of all COVID-19 patients in Latvia. We
conducted a retrospective cohort study, including 92
COVID-19 disease outpatients (age ≤ 18 years) and their
caregivers (parents or legal family representatives) from
March 12, 2020 (the date COVID-19 was declared a
state of emergency in Latvia), to December 1, 2020. A
real-time polymerase chain reaction (RT-PCR) for
SARS-CoV-2 was used, and the study included children
with a negative test result. Patients were tested systemat-
ically for viral co-infections. Caregivers had to provide
written consent for this. To identify the long-term con-
sequences of SARS-CoV-2 infection, all patients enrolled
in the study were evaluated by two pediatricians in a
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face-to-face visit according to a specially designed post-
COVID-19 symptom assessment protocol (supplemen-
tary material) developed based on previously published
literature about Long COVID in adults [2, 3, 9, 10].
Post-COVID-19 evaluation protocol consists of the fol-
lowing domains: physical and mental health, social and
psycho-emotional wellbeing. During the follow-up, we
collected demographic and epidemiological characteris-
tics, vaccination status, baseline chronic medical condi-
tions and clinical features during the acute phase of
SARS-CoV-2, as well as the clinical symptoms that were
persistent at the time of the first visit. We collected this
information in a structured questionnaire (which med-
ical staff filled in). For this data analysis, we excluded pa-
tients who had not consented to the follow-up visits or
who could not be reached, as well as those who showed
no symptoms at testing, or those in whom co-infections
were diagnosed. Descriptive statistics were used to
present the data. The ethics committee of Riga Stradins
University and the Institutional Review Board of Chil-
dren’s Clinical University Hospital (No. 6–1/07/35)
reviewed and approved the study protocol questionnaire
and informed consent forms.
Table 1 Characteristics of Symptomatic Children’s COVID-19
Cases (N = 92)
Characteristics Value
Median (interquartile range) age, years 12 (8–15)
Age group, No. (%):
1 month to < 1 year None
1–4 years 10 (11%)
5–9 years 21 (23%)
10–14 years 35 (38%)
15–18 years 26 (28%)




Seasonal influenza 12 (13%)
Complete vaccination 85 (92%)
Incomplete vaccination 12 (13%)
Total baseline chronic medical conditions, No. (%) 18 (20%)
Bronchial asthma 7 (8%)
Attention-deficit/hyperactivity disorder 3 (3%)
Atopic dermatitis 2 (2%)
Arthritis 1 (1%)
Patent ductus arteriosus 1 (1%)
Vegetative dystonia 1 (1%)
Congenital hypothyroidism 1 (1%)
Epilepsy 1 (1%)
Overactive bladder 1 (1%)
Exposure to the source of transmission, No. (%)
Contact with COVID19 positive patients within the
last 14 days
66 (72%)
Contact with group COVID-19 cases 35 (38%)
Contact with a person with fever / respiratory
symptoms or epidemiological communities in the
last 14 days
22 (24%)
Contact with a person who does not know the
COVID-19 test results within 14 days
18 (20%)
Traveling in the last 14 days 17 (18%)
Patients from a care center 2 (2%)
Acute COVID-19 symptoms, No. (%)
Distribution of temperature, No. (%)
37.2–37.5 °C 36 (39%)
≥ 37.5–38 °C 15 (16%)
38.1–39.0 °C 13 (14%)





Sore throat 29 (32%)
Table 1 Characteristics of Symptomatic Children’s COVID-19
Cases (N = 92) (Continued)
Characteristics Value
Loss of taste and/or smell 27 (29%)




Shortness of breath 10 (11%)
Drowsiness 7 (8%)




Sensory disturbances 4 (4%)
Sweatiness 2 (2%)
Epistaxis 2 (2%)
Periorbital edema 1 (1%)
Seizures 1 (1%)
Post–acute COVID-19 follow-up characteristics
Days since symptoms onset, median (interquartile range) 55 (30–104)




≥ 3 20 (22%)
Smane et al. Italian Journal of Pediatrics          (2021) 47:177 Page 2 of 4
We invited 189 patients who had been tested in an
ambulatory setting to participate in the study by tele-
phone, with 92 face-to-face follow-up first visits com-
pleted. Among the 189 patients, we excluded 62 from
the study who could not be reached, 27 who were not
willing to participate in the study and 8 who did not an-
swer the questions about symptoms. No co-infections
were observed in patients of the study group. The me-
dian age of the study group was 12 years (interquartile
range [IQR] = 8–15 years), 56 (61%) were boys. Overall,
18 children reported chronic medical conditions. The
median interval from the test to the first follow-up visit
was 55 days (IQR = 30–104 days). Among all 92 outpa-
tients during the acute phase of SARS-CoV-2 infection,
tiredness was the most commonly reported symptom in
42 (46%) and fever in 39 (42%), with headaches in 34
(37%), while a cough was present in 30 (33%) patients.
Fever was defined as an axillary temperature of 37.5 °C
or higher. The characteristics of the study population
are summarised in Table 1. At the time of the follow-up
visit, 45 (49%) were completely free of any COVID-19-
related symptoms, while 19% had 1 symptom, 10% had
2, and 22% had 3 or more. We have not looked at the
correlation between the persistence of symptoms and
distance from the acute phase of the infection. The
Figure shows that patients still commonly reported
tiredness (38%), loss of taste and/or smell (16%), and
headaches (15%) (Fig. 1). Sensory disturbances (photo-
phobia, sound sensitivity) occurred in 10 (11%) pa-
tients, while cognitive disturbances (memory,
attention, and information processing problems) were
present in 9 (10%). Other less common symptoms of
the cohort are displayed in Table 2.
Table 2 Post-COVID-19 follow-up clinical features
Symptoms Value %
Tiredness after sleep 18 20
Persistent fatique 17 18
Loss of taste and/or smell 15 16
Headache 14 15
Sensory disturbances 10 11
Cognitive disturbances 9 10
Prolonged fever 8 9
Stuffy nose 8 9
Joint pain 7 8
Dizziness 7 8
Chest pain 6 7
Cough 6 7
Dry mouth 6 7
Rhinorrhea 6 7
Decreased appetite 5 5
Myalgia 5 5
Orthostatic intolerance 4 4
Sore throat 4 4
Drowsiness 4 4
Red eye syndrome 3 3
Dry eyes 2 2
Shortness of breath 2 2
Sweatiness 2 2
Swollen lymph glands 2 2
Weight loss 1 1
Exercise intolerance 1 1
Microhematuria 1 1
Fig. 1 COVID-19-related symptoms in children during the acute phase of the disease and at the time of the follow-up visit
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To understand the frequency and nature of long-term
complications and persistent symptoms, we are continu-
ing our study and following the study design, which
consists of outpatient follow-up visits (at 1, 3, 6, 12, and
24months after COVID-19 onset) at which several do-
mains are evaluated according to a special questionnaire:
physical, mental, social and wellbeing. Researchers have
shown that even among young adults aged 18–34 years
with no chronic medical conditions, nearly one in five
reported prolonged COVID-19-related symptoms [3].
The most commonly reported were fatigue, loss of taste
and/or smell and headaches [3, 5]. Our study represents
the clinical features of paediatric post-acute COVID-19,
with tiredness, loss of taste and/or smell, and headaches
among those most commonly reported in outpatients.
Previous studies in children found similar presenting
symptoms, but they were more common in hospitalized
patients [6, 7]. According to our data, the most common
post-acute COVID-19 clinical features were noted in
children from 10 to 18 years. In conclusion, future stud-
ies assessing organ damage will be needed to better
understand and characterise Long COVID in children
[11]. This study has several limitations. Firstly, this was a
retrospective study. Secondly, this study includes a small
sample size of patients. Thirdly, the absence of a control
group made a comparison with one impossible.
In conclusion, up to 1–3 months after symptom onset,
51% of children with COVID-19 had complaints, mainly
tiredness, loss of taste/smell and headaches. A prolonged
multidisciplinary follow-up of patients with COVID-19
seems relevant, whatever the severity of the symptoms.
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